List of Excipients in Branded Drug FLUOROPLEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Almirall LLC	FLUOROPLEX	fluorouracil	16110-812	BENZYL ALCOHOL
Almirall LLC	FLUOROPLEX	fluorouracil	16110-812	ISOPROPYL MYRISTATE
Almirall LLC	FLUOROPLEX	fluorouracil	16110-812	MINERAL OIL

Fluoroplex Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

Fluoroplex is a prescription topical fluorouracil 1% cream used primarily for actinic keratosis. Its commercial opportunity is limited as a branded product but remains relevant for generic development, differentiated topical delivery, tolerability improvements, and combination dermatology products. The principal value is in excipient selection that improves spreadability, skin residence, patient adherence, packaging stability, and local tolerability without changing fluorouracil exposure materially.

What is Fluoroplex and what formulation does it contain?

Fluoroplex contains fluorouracil 1% in a topical cream dosage form. The FDA-approved indication is the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp. Fluorouracil produces local cytotoxic effects through interference with DNA and RNA synthesis in abnormal keratinocytes.[1]

The labeled formulation includes fluorouracil with a conventional cream base containing the following inactive ingredients:

Component	Primary formulation function
Benzyl alcohol	Preservative and solvent
Cetyl alcohol	Consistency agent and emollient
Glyceryl monostearate	Emulsifier and texture modifier
Isopropyl myristate	Emollient and penetration-enhancing solvent
Methylparaben	Preservative
Propylparaben	Preservative
Purified water	Aqueous phase
Stearyl alcohol	Consistency agent and emollient
White petrolatum	Occlusive emollient and viscosity modifier

The excipient system is a conventional oil-in-water or semisolid cream platform. Its commercial advantages are low manufacturing complexity, familiar dermatological handling, and broad patient acceptability. Its limitations include preservative sensitivity, potential variability in drug release, cream residue, and limited differentiation from generic fluorouracil products.

What patents protect Fluoroplex and its excipient system?

Fluoroplex's current commercial value is unlikely to depend on an active patent estate covering fluorouracil itself. Fluorouracil is an old small-molecule active ingredient, and conventional topical fluorouracil cream technology has been used for decades.

The relevant protection categories are:

1. Product-by-process or formulation patents.
2. Particle-size or polymorph claims.
3. Controlled-release or enhanced-penetration systems.
4. Combination products containing fluorouracil and another dermatological active.
5. Container-closure or dose-delivery systems.
6. Method-of-use claims for specific treatment regimens.

The original Fluoroplex formulation and its conventional excipients are unlikely to provide meaningful modern exclusivity on their own. Excipients such as petrolatum, cetyl alcohol, stearyl alcohol, parabens, and glyceryl monostearate are widely used and generally cannot support commercially strong composition claims without a narrowly defined interaction, ratio, performance parameter, or delivery effect.

A new formulation could support intellectual property if it claims a measurable technical result, such as:

• Improved fluorouracil release through human or animal skin.
• Reduced local irritation while maintaining lesion clearance.
• Reduced crystallization during storage.
• Improved content uniformity at low drug loading.
• A preservative-free multidose formulation with validated microbiological protection.
• A defined particle-size distribution or solvent system.
• A non-greasy vehicle with comparable clinical efficacy.
• A metered-dose package that delivers a reproducible amount per actinic lesion.

When does Fluoroplex lose exclusivity?

Fluoroplex is an old topical prescription product. Any original active-ingredient exclusivity has expired. The main market-access barriers are therefore regulatory equivalence, manufacturing quality, product availability, physician preference, and payer positioning rather than basic molecule protection.

Exclusivity category	Fluoroplex position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Biologic exclusivity	Not applicable
Pediatric exclusivity	No current commercial significance identified
Active-ingredient patent	Expired or commercially irrelevant
Formulation exclusivity	Must be assessed against any current listed patents and approved-label records
Trademark protection	Separate from FDA market exclusivity
Generic entry pathway	Generally an ANDA or, for materially different formulations, potentially a 505(b)(2) application

FDA approval of a generic topical product depends on the reference product, dosage form, strength, route, inactive-ingredient acceptability, product quality, and the applicable bioequivalence approach. FDA's topical dermatological guidance recognizes that in vitro release testing and other product-performance methods can be important for demonstrating equivalence.[2]

What is the Orange Book status of Fluoroplex?

Fluoroplex is regulated as a prescription drug rather than a biologic. Its Orange Book relevance is tied to the approved fluorouracil topical cream reference product and any patents or exclusivity periods listed for that product.[3]

An Orange Book review should examine:

• The currently designated reference-listed drug.
• Whether the reference product remains marketed.
• Listed patents and their expiration dates.
• Whether a generic applicant can file a Paragraph IV certification.
• Whether the reference product's dosage form and strength have changed.
• Whether the applicant is required to rely on a discontinued or withdrawn product.
• Whether an authorized generic or other equivalent product is available.

A Paragraph IV challenge would be commercially meaningful only if an unexpired listed patent remained enforceable. For an old conventional fluorouracil cream, the more likely route is a standard ANDA with Paragraph III certifications or no relevant listed-patent barrier, subject to the current Orange Book record.

Which excipients create the strongest commercial opportunities?

The largest opportunities are not new excipient identities. They are performance-led combinations of established excipients.

1. Preservative-free systems

Fluoroplex contains parabens and benzyl alcohol under the labeled formulation. A preservative-free system could target patients with contact sensitivity, compromised skin barriers, or repeated topical use.

Potential platforms include:

• Single-use sachets.
• Unit-dose airless pumps.
• Metered-dose tubes.
• Water-reduced creams.
• Anhydrous ointment or gel systems.

The principal regulatory challenge is microbial protection during use. A preservative-free multidose package must demonstrate container-closure integrity, in-use stability, and microbiological control under applicable FDA and USP expectations.[4]

2. Reduced-irritation cream systems

Fluorouracil treatment commonly causes erythema, burning, scaling, crusting, and inflammation as abnormal lesions respond. The inflammatory response is part of the pharmacology, so an excipient strategy cannot simply suppress all visible reaction without risking reduced treatment effect or altered patient behavior.

Useful design targets include:

• Lowering sting at application.
• Reducing evaporative drying.
• Improving skin feel after application.
• Minimizing residual greasiness.
• Avoiding known sensitizing preservatives.
• Limiting uncontrolled penetration into healthy skin.

Candidates may include skin-compatible humectants, lower-irritancy emulsifiers, lamellar lipid systems, and carefully selected silicone or hydrocarbon phases. Any excipient that changes fluorouracil delivery could affect local efficacy and would require comparative performance testing.

3. Improved drug-release control

Fluorouracil is a small, water-soluble molecule. Its release from a cream depends on water activity, drug solubility, partitioning between phases, viscosity, and the state of the drug in the formulation.

Commercially relevant formulation objectives include:

• Maintaining fluorouracil in a stable dissolved or controlled dispersed state.
• Avoiding precipitation during storage.
• Achieving consistent release across batches.
• Limiting an initial burst that may worsen irritation.
• Preserving adequate delivery to actinic lesions.

A formulation patent would be stronger if it linked a defined excipient ratio or physical property to in vitro release, skin permeation, chemical stability, or clinical tolerability.

4. Non-greasy and cosmetically acceptable vehicles

Many actinic keratosis patients are older and may treat visible areas of the face, scalp, ears, or hands. Cosmetic properties can influence adherence.

Commercially attractive vehicles include:

• Low-residue emulsions.
• Fast-spreading creams.
• Gel-creams.
• Hydroalcoholic gels where tolerability permits.
• Foam or spray systems for scalp application.
• Transparent or translucent products for daytime use.

A cosmetic improvement alone may not justify a 505(b)(2) product. It can support differentiation when paired with an objectively measured benefit such as improved adherence, consistent dosing, less product waste, or reduced irritation.

What formulations are protected by potential follow-on patents?

A follow-on Fluoroplex product could use several patentable architectures.

Formulation concept	Potential claim focus	Commercial value
Preservative-free cream	Composition plus package and in-use stability	Moderate
Airless pump cream	Dose delivery and oxygen or contamination control	Moderate
Fluorouracil gel-cream	Vehicle composition and release profile	Moderate
Lipid-based emulsion	Skin residence and tolerability	Moderate
Microparticle dispersion	Particle size, release, and stability	High if performance is demonstrated
Film-forming system	Residence time and controlled delivery	Moderate to high
Combination cream	Fluorouracil plus anti-inflammatory or keratolytic	High, subject to clinical and regulatory requirements
Scalp foam or spray	Coverage, convenience, and delivery	Moderate
Unit-dose sachet	Stability, dose uniformity, and contamination control	Moderate

Patent strength depends on claim breadth and the ability to demonstrate non-obvious performance. A claim covering "fluorouracil in a cream with a pharmaceutically acceptable excipient" would face substantial prior-art risk. A claim tied to a narrow excipient system, release range, stability result, or clinical outcome is more defensible but may be easier to design around.

How does Fluoroplex compare with competing fluorouracil products?

Fluoroplex is positioned at the lower 1% strength, while fluorouracil 5% cream and topical solutions represent other established dosage forms. The products are not automatically interchangeable because strength, formulation, indication, application schedule, vehicle, and labeling differ.

Product category	Typical strength	Dosage form	Strategic position
Fluoroplex	1%	Cream	Lower-strength branded topical option
Generic fluorouracil	5%	Cream	Established generic reference and price competitor
Fluorouracil topical solution	Commonly 2%	Solution	Alternative vehicle, often relevant to scalp or hair-bearing areas
Other branded fluorouracil products	Varies	Cream, solution, combination product	Differentiated delivery or combination treatment

The strongest competitive threat is from generic fluorouracil creams and solutions, not biosimilars. Fluoroplex is a small molecule, so the FDA biosimilar pathway does not apply. Competitive differentiation must come from formulation performance, convenience, supply reliability, clinical tolerability, or a new indication.

Which companies are challenging Fluoroplex?

Generic manufacturers of topical fluorouracil products are the principal competitive group. Their commercial strategy typically emphasizes:

• Lower acquisition cost.
• ANDA-based substitution.
• Multiple tube sizes.
• Contract manufacturing scale.
• Formulary and wholesaler access.
• Reliable supply of a mature topical product.

The market can include branded-generic manufacturers, specialty dermatology companies, contract development and manufacturing organizations, and firms pursuing 505(b)(2) reformulations.

A company evaluating entry should compare its product against both Fluoroplex and the clinically familiar 5% fluorouracil cream. A formulation that is merely equivalent to Fluoroplex but materially more expensive may have limited payer leverage.

What generic entry risks exist for Fluoroplex?

Generic entry risk is high at the molecule and dosage-form level because fluorouracil is mature and topical cream technology is established. The main risks are:

1. Rapid price erosion after approval.
2. Difficulty demonstrating meaningful differentiation.
3. Reference-product availability or discontinuation issues.
4. Variability in topical bioequivalence expectations.
5. Manufacturing complexity caused by low-dose uniformity requirements.
6. Stability problems involving crystallization or phase separation.
7. Container-closure interactions.
8. Local irritation differences that affect substitution or physician preference.

For a conventional ANDA, the most efficient strategy is usually to match the reference product's qualitative and quantitative excipient profile where feasible. A materially different excipient system can create formulation freedom but may increase bioequivalence, safety, and labeling burdens.

What manufacturing and intellectual-property barriers apply?

Manufacturing barriers are manageable but technically important. Fluorouracil 1% requires reliable content uniformity in a semisolid matrix. Critical process variables may include:

• Temperature during emulsification.
• Order of phase addition.
• Shear rate and mixing time.
• Drug dissolution or dispersion state.
• Cooling profile.
• Homogenization.
• Filling temperature.
• Tube or pump compatibility.
• Long-term and accelerated stability.

A follow-on product should generate a development package covering rheology, particle or droplet size, assay, degradation products, in vitro release, microbial quality, preservative effectiveness where relevant, and package performance.

The most defensible IP positions are likely to arise from:

• Narrow formulation windows that produce reproducible release.
• Improved stability under accelerated conditions.
• Specific package-delivery combinations.
• Reduced irritation demonstrated in comparative studies.
• New treatment regimens supported by clinical data.
• Combination products with separate therapeutic rationale.

What licensing opportunities exist for Fluoroplex-related products?

Licensing opportunities are more likely to involve technology than the Fluoroplex trademark. Relevant assets include:

• Dermatological cream platforms.
• Airless or metered-dose packaging.
• Film-forming topical systems.
• Preservative-free semisolids.
• In vitro release and topical bioequivalence methods.
• Combination-product clinical data.
• Contract manufacturing capacity for low-dose fluorouracil creams.

A licensee should avoid paying a premium for broad fluorouracil composition claims that do not include enforceable formulation limitations. The strongest transaction targets are platform technologies with demonstrated performance in fluorouracil or a closely related topical active, supported by issued claims and reproducible manufacturing data.

What is the revenue exposure and commercial outlook?

Public product-level revenue for Fluoroplex is generally not disclosed separately from broader dermatology portfolios. Its commercial outlook depends on whether the product is sold as a standalone branded product, included in a specialty dermatology portfolio, or supplied through a licensing or distribution arrangement.

The revenue pool is constrained by:

• Mature generic competition.
• Low switching costs for prescribers.
• Limited active-ingredient differentiation.
• Short treatment courses.
• Payer pressure.
• Availability of other fluorouracil strengths and vehicles.

The most credible commercial opportunities are:

1. A lower-irritation product with clinical evidence.
2. A preservative-free or unit-dose presentation.
3. A convenient scalp or facial delivery system.
4. A combination product that reduces treatment burden.
5. A reliable generic with superior supply and packaging.
6. A 505(b)(2) product supported by a differentiated delivery profile.

Key Takeaways

• Fluoroplex is a fluorouracil 1% prescription cream for actinic keratosis.
• Its conventional excipient system includes benzyl alcohol, cetyl alcohol, glyceryl monostearate, isopropyl myristate, parabens, purified water, stearyl alcohol, and white petrolatum.
• Original molecule and conventional formulation exclusivity are not the principal commercial barriers.
• Generic competition is the dominant market risk.
• The strongest excipient opportunities involve tolerability, release control, preservative reduction, packaging, and cosmetic acceptability.
• A conventional generic is more likely to use an ANDA; a materially differentiated formulation may require a 505(b)(2) strategy.
• Fluoroplex has no biosimilar risk because fluorouracil is a small molecule.
• Formulation patents need defined technical results, not generic excipient lists.
• Commercial upside is greater for a clinically differentiated delivery system than for an undifferentiated branded fluorouracil cream.

FAQs

Can a preservative-free Fluoroplex formulation be developed?

Yes. A preservative-free fluorouracil cream could use unit-dose packaging, an airless pump, an anhydrous base, or another system that controls microbial contamination during manufacture and use. The product would require appropriate stability, package-integrity, and microbiological validation.

Would changing the Fluoroplex excipients require a new FDA application?

A generic with materially different excipients may still use an ANDA if it meets applicable sameness and equivalence requirements. A clinically or technologically differentiated formulation may require a 505(b)(2) application, particularly if it relies on new delivery, dosing, or comparative clinical claims.

Is fluorouracil 1% cream interchangeable with fluorouracil 5% cream?

No automatic interchangeability should be assumed. Strength, vehicle, labeling, treatment schedule, application site, and approved indication can differ. Substitution depends on the product's regulatory status and applicable state pharmacy law.

Can an excipient combination receive patent protection?

Yes, but protection is stronger when the combination is defined by specific concentrations, physical properties, processing conditions, or demonstrated performance. Broad claims covering familiar cream excipients are vulnerable to prior-art and obviousness challenges.

What is the best commercial niche for a new Fluoroplex competitor?

The strongest niche is a topical product that combines clinically demonstrated lower irritation or better adherence with a convenient delivery system, such as a preservative-free pump, unit-dose package, or low-residue formulation.

References

1. DailyMed. (n.d.). Fluoroplex- fluorouracil cream: Prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Topical dermatologic corticosteroids: In vitro release test studies. FDA.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
4. United States Pharmacopeial Convention. (2023). General chapter <51>: Antimicrobial effectiveness testing. In United States Pharmacopeia and National Formulary. en-US.